{"groups":[{"description":"Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV","id":"FG000","title":"Treatment (Nivolumab)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Declining health"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Still receiving treatment at the time of the analysis"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"Treated"},{"achievements":[{"comment":"One patient experienced disease progression in cycle 1 and an AE form was not submitted.","groupId":"FG000","numSubjects":"46"}],"type":"Treated and Reported Adverse Event Data"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until progression or intolerability. At the time of the final analysis of the data, 9 patients were still receiving protocol treatment.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Z1D, patients had to have complete loss of nuclear expression of MLH1 or MSH2 MMR gene products by IHC.","recruitmentDetails":"Subprotocol Z1D was activated in NCI-MATCH on May 31, 2016. Patients enrolled for screening by the MATCH assay between this date and the end of screening enrollment in May 2017, were evaluated for MSH2 and MLH1 expression by immunohistochemistry (IHC). In the end, 47 patients were enrolled to the subprotocol."}